scholarly journals Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy

2020 ◽  
Vol 7 (4) ◽  
pp. 134-143
Author(s):  
Nicholas Lim ◽  
Dupinder Singh ◽  
Scott Jackson ◽  
John R. Lake
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Transplant Recipients ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Liver Transplant Recipients

scholarly journals Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study

Hepatology ◽  
2017 ◽  
Vol 66 (4) ◽  
pp. 1090-1101 ◽  
Author(s):  
Varun Saxena ◽  
Vandana Khungar ◽  
Elizabeth C. Verna ◽  
Josh Levitsky ◽  
Robert S. Brown ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Liver Transplant ◽  
Transplant Recipients ◽  
Safety And Efficacy ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Liver Transplant Recipients

Therapy With Direct-Acting Antiviral Agents for Hepatitis C in Liver Transplant Recipients

2018 ◽  
Vol 50 (2) ◽  
pp. 631-633 ◽  
Author(s):  
F. Nogueras López ◽  
A. López Garrido ◽  
E.J. Ortega Suazo ◽  
F. Vadillo Calles ◽  
F. Valverde López ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Liver Transplant ◽  
Antiviral Agents ◽  
Transplant Recipients ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Liver Transplant Recipients ◽  
Direct Acting Antiviral Agents

scholarly journals Impact of direct‐acting antivirals for hepatitis C virus therapy on tacrolimus dosing in liver transplant recipients

2019 ◽  
Vol 21 (3) ◽  
pp. e13078 ◽  
Author(s):  
Alexandra L. Bixby ◽  
Linda Fitzgerald ◽  
Rachael Leek ◽  
Jessica Mellinger ◽  
Pratima Sharma ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Transplant Recipients ◽  
Direct Acting Antivirals ◽  
Direct Acting ◽  
Liver Transplant Recipients

scholarly journals Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis

Viruses ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1831
Author(s):  
Jennifer Wellington ◽  
Andrew Ma ◽  
Shyam Kottilil ◽  
Bharath Ravichandran ◽  
Jennifer Husson ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Antiviral Treatment ◽  
Transplant Recipients ◽  
Direct Acting Antiviral ◽  
Related Disease ◽  
Timing Of Treatment ◽  
Direct Acting ◽  
Liver Transplant Recipients

Liver transplantation for hepatitis C virus (HCV)-related disease has the lowest five-year graft survival among all liver transplant recipients. Graft failure due to accelerated fibrosis from unrestrained HCV replication is common. Optimal timing of HCV treatment with direct-acting antiviral agents remains unknown. We compared HCV liver transplant recipients successfully treated for HCV before transplant to those treated within 1 year of transplant to determine if graft fibrosis, measured by Fib-4 scores, differs with timing of treatment. Fib-4 scores less than or equal to 1.45 defined minimal fibrosis and greater than 1.45 defined greater than minimal fibrosis. We identified 117 liver transplant recipients: 52 treated before transplantation and 65 treated within 1 year of transplantation. Overall, 34% of recipients had minimal fibrosis, and the likelihood of having minimal fibrosis following treatment and liver transplantation did not differ by timing of treatment. The odds ratio of having greater than minimal fibrosis was 0.65 (95% CI 0.30, 1.42) among those treated within 1 year after transplantation compared to those treated before transplantation (p-value 0.28). Importantly, nearly 2/3 of these patients had evidence of fibrosis progression one year after sustained virologic response, supporting recommendations for early antiviral-based treatment to prevent accumulation of HCV-related disease.

Sign in / Sign up

Export Citation Format

Share Document